Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPSC Century Therapeutics	$0.58 -4.1%	$0.54	$0.34 ▼ $3.30	$49.58M	1.77	525,612 shs	757,374 shs
KRON Kronos Bio	$0.89 +1.4%	$0.78	$0.65 ▼ $1.60	$53.73M	1.63	344,865 shs	347,765 shs
ME 23andMe	$0.50 -35.3%	$0.50	$0.53 ▼ $10.81	$13.36M	1.19	1.39 million shs	29.28 million shs
QNCX Quince Therapeutics	$1.43 +19.2%	$1.06	$0.51 ▼ $2.45	$65.02M	0.8	297,075 shs	654,736 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPSC Century Therapeutics	0.00%	-6.64%	+11.21%	-3.50%	-82.35%
KRON Kronos Bio	0.00%	+2.36%	+26.61%	-5.04%	-30.27%
ME 23andMe	0.00%	0.00%	0.00%	-74.06%	-93.96%
QNCX Quince Therapeutics	0.00%	+22.22%	+70.44%	-0.69%	+100.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IPSC Century Therapeutics	2.456 of 5 stars	3.5	4.0	0.0	0.0	0.9	1.7	0.6
KRON Kronos Bio	3.2534 of 5 stars	3.2	3.0	0.0	0.0	1.9	4.2	1.3
ME 23andMe	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	3.63 of 5 stars	3.6	5.0	0.0	0.0	2.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IPSC Century Therapeutics	3.00	Buy	$4.20	629.93% Upside
KRON Kronos Bio	2.33	Hold	$1.63	82.05% Upside
ME 23andMe	1.00	Sell	N/A	N/A
QNCX Quince Therapeutics	3.29	Buy	$8.00	459.44% Upside

Current Analyst Ratings Breakdown

Latest ME, QNCX, IPSC, and KRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/4/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
5/16/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
4/3/2025	IPSC Century Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
3/28/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/25/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $4.00
3/24/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $7.00
3/24/2025	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
3/22/2025	ME 23andMe	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
3/21/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
3/20/2025	IPSC Century Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$4.00 ➝ $2.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPSC Century Therapeutics	$114.90M	0.43	N/A	N/A	$3.06 per share	0.19
KRON Kronos Bio	$9.19M	5.93	N/A	N/A	$2.73 per share	0.33
ME 23andMe	$208.78M	0.06	$0.54 per share	0.93	$2.34 per share	0.21
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$1.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPSC Century Therapeutics	-$136.67M	-$0.29	N/A	N/A	N/A	-4,837.73%	-61.66%	-31.78%	8/14/2025 (Estimated)
KRON Kronos Bio	-$112.67M	-$1.07	N/A	N/A	N/A	-867.66%	-64.55%	-48.18%	8/6/2025 (Estimated)
ME 23andMe	-$666.70M	-$15.45	N/A	∞	N/A	-183.39%	-170.07%	-62.13%	N/A
QNCX Quince Therapeutics	-$31.39M	-$1.39	N/A	N/A	N/A	N/A	-53.27%	-22.73%	8/12/2025 (Estimated)

Latest ME, QNCX, IPSC, and KRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	$0.89	+$1.20	$0.89	$45.52 million	$109.16 million
5/13/2025	Q1 2025	QNCX Quince Therapeutics	-$0.24	-$0.34	-$0.10	-$0.34	N/A	N/A
3/24/2025	Q4 2024	QNCX Quince Therapeutics	-$0.19	-$0.28	-$0.09	-$0.28	N/A	$0.17 million
3/19/2025	Q4 2024	IPSC Century Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	$0.67 million	$4.18 million
3/18/2025	Q4 2024	KRON Kronos Bio	-$0.30	-$0.43	-$0.13	-$0.43	$1.00 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
KRON Kronos Bio	N/A	N/A	N/A	N/A	N/A
ME 23andMe	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPSC Century Therapeutics	N/A	10.39	10.39
KRON Kronos Bio	N/A	8.32	8.32
ME 23andMe	N/A	1.05	0.91
QNCX Quince Therapeutics	0.33	9.53	9.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPSC Century Therapeutics	50.20%
KRON Kronos Bio	64.09%
ME 23andMe	36.10%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
IPSC Century Therapeutics	5.00%
KRON Kronos Bio	24.40%
ME 23andMe	26.32%
QNCX Quince Therapeutics	20.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPSC Century Therapeutics	170	86.16 million	79.25 million	Optionable
KRON Kronos Bio	100	61.05 million	45.62 million	Optionable
ME 23andMe	770	26.83 million	19.77 million	Not Optionable
QNCX Quince Therapeutics	60	45.47 million	36.61 million	Optionable

ME, QNCX, IPSC, and KRON Headlines

Recent News About These Companies

Quince Therapeutics raises $11.5 million in private placement

June 14 at 12:50 PM | investing.com

Quince Therapeutics Raises $11.5M in Private Placement

June 13 at 6:14 PM | tipranks.com

Quince Therapeutics' (QNCX) Buy Rating Reaffirmed at D. Boral Capital

June 13 at 8:16 AM | marketbeat.com

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

June 12 at 5:15 PM | businesswire.com

Quince Therapeutics' (QNCX) Buy Rating Reiterated at D. Boral Capital

June 6, 2025 | americanbankingnews.com

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

June 3, 2025 | businesswire.com

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

May 15, 2025 | seekingalpha.com

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 14, 2025 | finance.yahoo.com

Quince Therapeutics to Present at Citizens Life Sciences Conference

April 30, 2025 | businesswire.com

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

April 3, 2025 | businesswire.com

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD)

March 27, 2025 | markets.businessinsider.com

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

March 24, 2025 | businesswire.com

Oppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform Recommendation

March 24, 2025 | msn.com

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

February 7, 2025 | businesswire.com

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 5, 2025 | businesswire.com

Quince Therapeutics gets USPTO notice of allowance in Ataxia-Telangiectasia

February 4, 2025 | markets.businessinsider.com

Quince Therapeutics secures USPTO nod for A-T treatment patent

February 4, 2025 | msn.com

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

February 4, 2025 | businesswire.com

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

January 27, 2025 | finance.yahoo.com

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

January 24, 2025 | finance.yahoo.com

Quince Therapeutics initiated with a Buy at Brookline

December 19, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy
By Chris Markoch | May 29, 2025
View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy
Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
By Leo Miller | June 3, 2025
View Among the Market’s Most Shorted: 2 Firms With +40% Short Interest

ME, QNCX, IPSC, and KRON Company Descriptions

Century Therapeutics NASDAQ:IPSC

$0.58 -0.02 (-4.10%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.58 +0.00 (+0.80%)

As of 06/13/2025 07:36 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Kronos Bio NASDAQ:KRON

$0.89 +0.01 (+1.43%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.88 -0.01 (-1.19%)

As of 06/13/2025 04:15 PM Eastern

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

23andMe NASDAQ:ME

$0.50 -0.27 (-35.32%)

Closing price 03/28/2025

Extended Trading

$0.50 0.00 (0.00%)

As of 03/28/2025 08:00 PM Eastern

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Quince Therapeutics NASDAQ:QNCX

$1.43 +0.23 (+19.17%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.37 -0.06 (-4.13%)

As of 06/13/2025 07:50 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time